Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

被引:3
|
作者
Galindo-Oseguera, Evelyn [1 ]
Pinto-Almazan, Rodolfo [2 ]
Arellano-Ramirez, Alfredo [3 ]
Gasca-Lopez, Gilberto Adrian [3 ]
Ocharan-Hernandez, Maria Esther [2 ]
Calzada-Mendoza, Claudia C. [2 ]
Castillo-Cruz, Juan [2 ]
Martinez-Herrera, Erick [2 ,4 ]
机构
[1] Inst Politecn Nacl, Escuela Super Med, Mexico City 11340, DF, Mexico
[2] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Mexico City 11340, DF, Mexico
[3] Hosp Reg Alta Especial Ixtapaluca, Ixtapaluca 56530, Mexico
[4] SERGAS UVIGO, Efficiency Qual & Costs Hlth Serv Res Grp EFISALU, Galicia Sur Hlth Res Inst IIS Galicia Sur, Vigo 36213, Spain
关键词
SARS-CoV-2; COVID-19; risk factors; survival factors; mortality factors; OXYGEN-THERAPY; DISEASE;
D O I
10.3390/healthcare11070932
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
During the pandemic, some mortality-related factors were age, sex, comorbidities (obesity, diabetes mellitus, and hypertension), recovery time, hospitalizations, and biochemical markers. The present work aimed to identify the mortality and survival factors in adults with moderate and severe pneumonia due to COVID-19 during the first and second waves of the pandemic in Mexico at a third-level hospital (High-Specialty Regional Hospital of Ixtapaluca (HRAEI), Ixtapaluca, Estado de Mexico, Mexico). A database was generated using information from the electronic clinical records of patients hospitalized from December 2021 to August 2022. Survival analysis was performed associating age, sex, longer recovery times, and some drugs. The risk factors found were age in the patients between 40 and 60 years (OR = 1.70), male sex (OR = 1.53), the presence of comorbidities (OR = 1.66) and hypertension (OR = 2.19), work occupation (construction workers OR = 5.22, factory workers OR = 3.13, unemployed OR = 2.93), the prehospital use of metamizole sodium (OR = 2.17), cough (OR = 1.73), and in-hospital oxygen therapy (reservoir mask OR = 6.6). The survival factors found in this study were working in the healthcare field (OR = 0.26), the prehospital use of certain medications (paracetamol OR = 0.65, dexamethasone OR = 0.55, and azithromycin OR = 0.47), presenting ageusia (OR = 0.5) and hyporexia (OR = 0.34), and the time using in-hospital oxygen therapy (device 1 OR = 0.72). Prehospital treatment needs to be reevaluated as dexamethasone and azithromycin proved to be protective factors. Likewise, providing aggressive oxygen therapy during hospital admission decreased mortality risk.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS
    Afsin, Emine
    Demirkol, Muhammed Emin
    [J]. ACTA CLINICA CROATICA, 2023, 62 (01) : 106 - 114
  • [2] preditive factors of severe outcome in patients with covid-19 pneumonia
    Donia, Belkhir
    Maalej, Mariem
    Blibech, Hana
    Snene, Houda
    Jbali, Aymen
    Wadhane, Israa
    Kaabi, Line
    Laater, Ahmed
    Mehiri, Nadia
    Ben Salah, Nozha
    Louzir, Bechir
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] NIV IN MODERATE TO SEVERE ARDS DUE TO COVID-19 PNEUMONIA: A RETROSPECTIVE COHORT STUDY
    BOTSCH, A.
    ORAVEC, M.
    RAPIER, B.
    GOFF, L.
    DESMETT, A.
    [J]. CHEST, 2022, 161 (06) : 601A - 601A
  • [4] Association of lymphocyte subsets with mortality in severe COVID-19 pneumonia patients
    Ashrafi, Farzaneh
    Nematollahi, Pardis
    Salmasi, Mehrzad
    Hedayat, Arash
    Amra, Babak
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [5] Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study
    Mahendra, M.
    Nuchin, Abhishek
    Kumar, Ranjith
    Shreedhar, S.
    Mahesh, Padukudru Anand
    [J]. ADVANCES IN RESPIRATORY MEDICINE, 2021, 89 (02) : 135 - 144
  • [6] Myocardial injury and risk factors for mortality in patients with COVID-19 pneumonia
    Yang, Chongtu
    Liu, Fen
    Liu, Wei
    Cao, Guijuan
    Liu, Jiacheng
    Huang, Songjiang
    Zhu, Muxin
    Tu, Chao
    Wang, Jianwen
    Xiong, Bin
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 326 : 230 - 236
  • [7] Predictive factors for disease progression in moderate to severe COVID-19 patients
    Boubaker, Nouha
    Louhaichi, Sabrine
    Khalfallah, Ikbel
    Belkhir, Safa
    Ferchichi, Mariem
    Ammar, Jamel
    Hamdi, Besma
    Hamzaoui, Agnes
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [8] COVID-19 severe pneumonia in cancer patients: Impact and predictive factors
    Peinado, P.
    Sanz Garcia, E.
    Moreno, I.
    Dorta, M.
    Alvarez, B.
    Alvarez Gallego, R.
    Madurga, R.
    Ugidos, L.
    Rodriguez Pascual, J.
    Munoz, C.
    Garcia-Rico, E.
    Cubillo, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1024 - S1024
  • [9] Tomographic findings and mortality in patients with severe and critical pneumonia with COVID-19 diagnosis
    Jimenez-Zarazua, O.
    Velez-Ramirez, L. N.
    Hernandez-Ramirez, A.
    Arevalo-Rivas, B., I
    Galvan-Casas, M. A.
    Garcia-Zavala, G. U.
    Mondragon, J. D.
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2022, 40
  • [10] Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
    Gokhale, Yojana
    Mehta, Rakshita
    Karnik, Nitin
    Kulkarni, Uday
    Gokhale, Sushant
    [J]. ECLINICALMEDICINE, 2020, 24